Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 19.69
+0.43 (2.23%)
Nov 13, 2026, 3:04 PM CST
Jafron Biomedical Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 2,066 | 2,012 | 2,677 | 1,922 | 2,491 | 2,675 |
Revenue Growth | 1.41% | -24.86% | 39.27% | -22.84% | -6.88% | 37.15% |
Gross Profit Gross Profit Growth | 1,600 | 1,571 | 2,157 | 1,531 | 2,051 | 2,273 |
Operating Income Operating Income Growth | 824.96 | 708.59 | 997.98 | 482.98 | 926.66 | 1,324 |
Net Income Net Income Growth | 654.24 | 532.82 | 820.2 | 436.49 | 889.56 | 1,197 |
Earnings Per Share EPS Growth | 0.84 | 0.69 | 1.05 | 0.55 | 1.12 | 1.49 |
EPS Growth | 33.51% | -34.29% | 90.91% | -50.89% | -24.83% | 37.96% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Medical Device Manufacturing Industry Medical Device Manufacturing Industry Growth | 2,061 | 2,006 | 2,670 | 1,918 | 2,485 | 2,675 |
Other Other Growth | - | 5.34 | 7.81 | 4.78 | 5.96 | - |
Total Total Growth | 2,066 | 2,012 | 2,677 | 1,922 | 2,491 | 2,675 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 2,842 | 2,516 | 2,318 | 2,810 | 2,559 | 2,469 |
Total Debt Total Debt Growth | 1,300 | 1,235 | 1,386 | 1,675 | 1,276 | 917.55 |
Net Cash (Debt) Net Cash Growth | 1,542 | 1,280 | 931.31 | 1,135 | 1,283 | 1,552 |
Net Cash Growth | 46.13% | 37.49% | -17.97% | -11.49% | -17.34% | -1.47% |
Net Cash Per Share Net Cash Per Share Growth | 1.98 | 1.66 | 1.19 | 1.43 | 1.62 | 1.93 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 887.14 | 721.22 | 1,051 | 916.74 | 883.8 | 1,249 |
Capital Expenditures CapEx Growth | -179.27 | -172.59 | -235.14 | -247.25 | -475.89 | -537.41 |
Free Cash Flow Free Cash Flow Growth | 707.88 | 548.63 | 815.85 | 669.49 | 407.91 | 712 |
Free Cash Flow Growth | 22.32% | -32.75% | 21.86% | 64.13% | -42.71% | 18.59% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 77.44% | 78.11% | 80.57% | 79.67% | 82.33% | 84.97% |
Operating Margin | 39.92% | 35.22% | 37.28% | 25.12% | 37.19% | 49.48% |
Pretax Margin | 37.91% | 32.81% | 37.61% | 27.10% | 40.81% | 52.60% |
Profit Margin | 31.66% | 26.48% | 30.64% | 22.71% | 35.70% | 44.73% |
FCF Margin | 34.26% | 27.27% | 30.47% | 34.83% | 16.37% | 26.61% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.520 | 0.520 | 0.800 | 0.400 | 0.670 | 0.900 |
Dividend Per Share Growth | -35.00% | -35.00% | 100.00% | -40.30% | -25.56% | 36.36% |
Dividend Yield | 2.64% | 2.64% | 2.73% | 1.75% | 2.16% | 1.72% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 23.43 | 28.59 | 27.70 | 40.68 | 27.81 | 35.64 |
Forward PE | 24.16 | 19.57 | 20.91 | 20.46 | 14.20 | 31.28 |
P/FCF Ratio | 21.54 | 27.76 | 27.85 | 26.52 | 60.65 | 59.91 |
PS Ratio | 7.38 | 7.57 | 8.49 | 9.24 | 9.93 | 15.94 |